ReviewHematology/oncology clinics of North America2014

Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.

Annette E Hay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.